MarketPulse

quality of life

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Moonlake Immunotherapeutics

MoonLake's Sonelokimab Sustains Strong Phase 3 Results in Hidradenitis Suppurativa

MoonLake reports Week 40 Phase 3 data for sonelokimab showing 62% HiSCR75 response rates in hidradenitis suppurativa with no new safety signals.
MLTXPhase 3 clinical trialquality of life
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Alumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor
The Motley FoolThe Motley Fool··Dana George

Motley Fool Names Top 10 Retirement Destinations for 2026

Motley Fool identifies top 10 retirement destinations based on survey of 2,000 retirees, evaluating quality of life, healthcare, housing, costs, crime, taxes, and climate. Featured cities include Asheville, Charleston, and St. Augustine.
KOhealthcarequality of life
GlobeNewswire Inc.GlobeNewswire Inc.··Urogen Pharma Ltd.

Bladder Cancer Survey Reveals High Recurrence Fear, Procedural Burden Among Patients

BCAN survey of 1,100+ bladder cancer patients shows 80% experience recurrence fear, exceeding 90% in under-50 cohort. UroGen emphasizes need for treatments balancing tumor control with quality of life.
URGNquality of lifebladder cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria